US Patent Issued to Revitope on July 7 for "Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells" (Massachusetts Inventor)

ALEXANDRIA, Va., July 7 -- United States Patent no. 12,673,993, issued on July 7, was assigned to Revitope Ltd. (Hertfordshire, Great Britain).

"Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells" was invented by Mark Cobbold (Winchester, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A targeted T-cell engaging agent for treating a condition characterized by the presence of unwanted cells includes (a) a targeting moiety that is capable of targeting the unwanted cells; (b) a first T-cell engaging domain capable of T-cell engaging activity when binding a second T-cell engaging domain, wherein the second T-cell engaging domain is not part of t...